PDE5A and pulmonary arterial hypertension: A data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), which included patients with “typical” PAH, “atypical” PAH (PAH and a high burden of cardiovascular comorbidities), and PH-HFpEF, showed an improvement in functional class, exercise capacity, and natriuretic peptides in 226 patients with PH-HFpEF who received pulmonary vasodilators, predominantly PDE5 inhibitors [124].